In­side Ver­tex 3.0: Can Resh­ma Ke­wal­ra­mani re­peat one of biotech's biggest suc­cess sto­ries 'a­gain and again and again'?

Last year
People
In Focus

FDA+ roundup: Flur­ry of guid­ance doc­u­ments, up­dat­ed risk cri­te­ria for Covid-19 mAbs, per­son­nel moves and more

Last year
FDA+

Lega­cies: 60 bio­phar­ma pi­o­neers over 60 who helped birth a tech rev­o­lu­tion in the mak­ing

Last year
People
Special

Jim Wil­son and Tachi Ya­ma­da are at it again — launch­ing a 2nd-gen gene ther­a­py com­pa­ny with an ap­petite for risk, glob­al vi­sion and $200M to gam­ble with

Last year
Startups

In­sid­er ac­count of Roivan­t's SPAC deal — and that $7.3B val­u­a­tion — re­veals a few se­crets as Matt Gline po­si­tions the com­pa­ny as the new ‘Big Phar­ma’

Last year
Financing
Bioregnum

'Dude, you're get­ting a Del­l' — as a new deep-pock­et biotech in­vestor

Last year
Financing
Bioregnum

FDA un­veils six ICH guide­lines ahead of meet­ing with Health Cana­da

Last year
Pharma
FDA+

A clos­er look at the FDA’s more than 700 pan­dem­ic-re­lat­ed record re­quests to re­place on­site in­spec­tions

Last year
FDA+
Manufacturing

Let’s make that $1B-plus: Abing­worth gath­ers more cash, this time for its late-stage pok­er game. And we learned that even a biotech nu­clear win­ter has its ad­van­tages

Last year
Financing
Bioregnum

FDA ex­tends re­search agree­ment with MIT-li­censed or­gan-on-chip sys­tems

Last year
Pharma
FDA+

In quest to meet user fee goals, FDA’s per­for­mance con­tin­ues down­ward trend

Last year
Pharma
FDA+

Josh Bilenker and Jeff En­gel­man bun­dle a moth­er lode of cash for their stealthy start­up, at­tract­ing a who's who of biotech in­vestors

Last year
Startups
Bioregnum

ICH plots ma­jor over­haul of good clin­i­cal prac­tice guide­line

Last year
R&D
FDA+

Vivek Ra­maswamy and Matt Gline swoop in­to Nas­daq on the wings of Jim Mom­tazee's SPAC with a $7B-plus Roivant de­but ready to do some deals

Last year
Financing

More in­fo on drug re­view time­lines? HHS and FDA pull Trump HHS’ last-minute pledge

Last year
Pharma
FDA+

A new gene ther­a­py play­er de­buts in LA with 2 start­up VCs at its back, Ab­b­Vie on board with a $90M cash up­front and big plans to up­end the field

Last year
Startups

FDA warns Ac­celeron of pos­si­ble fines for not post­ing re­sults from failed tri­al

Last year
FDA+

Ex­clu­sive: Ohana, Flag­ship's big bet on fer­til­i­ty treat­ments, shuts down and lays off staff af­ter VC pulls the plug

Last year
Startups

Ex­clu­sive: Ul­ti­mate biotech in­sid­er Dan Lynch takes his 30 years of ex­pe­ri­ence to GV to fill a new­ly-cre­at­ed post

Last year
People

How the SCO­TUS de­ci­sion to gut the FTC could help bio­phar­ma com­pa­nies

Last year
Pharma
FDA+

Law pro­fes­sors call for FDA to dis­close all safe­ty and ef­fi­ca­cy da­ta for drugs

Last year
Pharma
FDA+

Why re­mote drug man­u­fac­tur­ing eval­u­a­tions won't re­al­ly re­duce FDA's back­log of in­spec­tions

Last year
FDA+
Manufacturing

Ex­clu­sive: Genen­tech's for­mer Tecen­triq 'CEO' jumps ship to head up com­mer­cial at an on­colyt­ic virus play­er

Last year
People

Ver­sant pulls the wraps off of near­ly $1B in 3 new funds out to build the next fleet of biotech star­tups. And this new gen­er­a­tion is built for speed

Last year
Financing
Startups
First page Previous page 78910111213 Next page Last page